2024-10-07 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:**  Pfizer Inc. is a multinational pharmaceutical corporation that researches, develops, manufactures, and markets a wide range of medicines and vaccines.

**1. Performance Analysis:**

* **Cumulative Return:** Pfizer Inc. (PFE) has experienced a cumulative return of -12.94%, while the S&P 500 (VOO) has yielded a return of 133.14%. This indicates that PFE has underperformed significantly compared to the benchmark index.
* **Relative Performance:** PFE is currently lagging behind the S&P 500 by a substantial margin.  The current relative performance stands at -146.08, which represents 0.25 on a scale where 100 is the maximum deviation from the minimum.

**2. Recent Price Action:**

* **Closing Price:** $28.58
* **5-Day Moving Average:** $28.63
* **20-Day Moving Average:** $29.24
* **60-Day Moving Average:** $29.28

PFE's current price is slightly below its recent moving averages, suggesting a potential downward trend in the short term.

**3. Technical Indicators:**

* **RSI:** 21.8.  This indicates that PFE is currently in oversold territory, suggesting a potential rebound.
* **PPO:** -0.39.  This shows that the short-term momentum is weaker than the long-term momentum, potentially indicating further downward movement.
* **Delta_Previous_Relative_Divergence:** -7.79. This suggests that PFE's recent performance is diverging negatively compared to its previous price trend.
* **Expected Return:** 0.0%. Based on the current market conditions, the 5-year expected return for PFE is negligible, considering its recent performance compared to the S&P 500 (VOO).

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

Pfizer's recent earnings have been volatile, with the most recent quarter showing a beat on EPS expectations.  However,  the overall trend indicates a potential downward pressure on future earnings, which needs to be monitored closely.

**5. News and Recent Issues:**

* Recent Market Outlook for PFE:  Analysts are cautious about PFE's future performance due to its lagging performance compared to the market, and a potential decrease in demand for its COVID-related products. 
* Analyst Opinions and Performance Highlights:  Several analysts have downgraded their ratings on PFE stock due to concerns about its slowing revenue growth, competition in the pharmaceutical sector, and overall market volatility.
* **Finbold.com** has reported that Pfizer's stock has faced significant headwinds in recent months, primarily due to a sharp decline in demand for its COVID-19 vaccine and treatment products.

**6.  Overall Analysis:**

Pfizer Inc. (PFE) currently presents a mixed outlook. While the stock appears to be oversold based on the RSI, and its recent earnings beat expectations, its relative underperformance against the S&P 500, declining momentum indicated by PPO, and potential revenue slowdown due to decreased demand for COVID-related products, raises concerns for investors.  It is essential to monitor the stock's performance closely, particularly its earnings, revenue, and competitive landscape.

**7. Recommendations:**

Investors seeking a long-term investment might want to reconsider PFE at this point, given the uncertainty surrounding its future prospects.  However, those with a shorter-term perspective might find an entry point considering the oversold RSI. It is crucial to conduct thorough research and consider individual risk tolerance before making any investment decisions.
